- Exchange: NASDAQ CM
- Sector: Consumer, Non-cyclical
- Industry: Biotechnology
- Sub-Industry: Medical-Biomedical/Gene
Dynavax Technologies Corp
Add to PortfolioDVAX:US
3.6400 USD 0.0100 0.27%As of 20:10:00 ET on 05/25/2012.
Snapshot for Dynavax Technologies Corp (DVAX)
| Open: | 3.6100 | Day's Range: | 3.6000 - 3.7000 | Volume: | 980,257 | Bid: | 3.6400 |
|---|---|---|---|---|---|---|---|
| Previous Close: | 3.6500 | 52wk Range: | 1.7500 - 5.3400 | 1-Yr Rtn: | +29.54% | Ask: | 3.6500 |
Key Statistics for DVAX
| Current P/E Ratio (ttm) | - |
|---|---|
| Estimated P/E (12/2012) | - |
| Earnings Per Share (USD) (ttm) | -0.3500 |
| Est. EPS (USD) (12/2012) | -0.4070 |
| Est. PEG Ratio | - |
| Market Cap (M USD) | 634.00 |
| Shares Outstanding (M) | 174.18 |
| Enterprise Value (M USD) (ttm) | 540.48 |
| Enterprise Value/EBITDA (ttm) | - |
| Price/Book (mrq) | 6.4510 |
| Price/Sale (ttm) | 21.8679 |
| Dividend Indicated Gross Yield | 0.0000 |
| Next Earnings Announcement | 07/20/2012 |
More DVAX Key Statistics
mrq = Most Recent Quarter; ttm = Trailing Twelve Months
Financials for DVAX
- Operating
- Investing
- Financing (M/USD)
Company Profile & Key Executives for DVAX
Dynavax Technologies Corporation discovers, develops, and is seeking to commercialize products based on immunostimulatory sequences. The Company is developing products to treat and prevent allergies, infectious diseases, and chronic inflammatory diseases using approaches that alter immune system responses in specific ways.
| Dino DinaChief Executive Officer | J Tyler MartinPresident |
| Jennifer LewVP:Finance | Steven F TuckVP:Global Technical Operations |
Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.
Sponsored Links
Top Forex Trading Resources
Advertisement
Advertisement
Advertisements
Rate this Page